MarketPulse — Real-Time Financial News & Market Analysis

Nvidia and Meta emerge as top AI stock picks for 2026, trading at reasonable 22x and 21x forward earnings while demonstrating exceptional growth and financial strength.

Willis and Circle Asia launch Asia's first specialized insurance facility for art collectors and galleries, featuring lower premiums, comprehensive coverage, and digital integration.

Securities class action filed against uniQure alleging FDA approval misrepresentations. April 13, 2026 deadline for lead plaintiff claims.

Securities class action filed against $PYPL for allegedly making false statements about 2027 financial targets and Branded Checkout growth. April 20, 2026 deadline for lead plaintiff claims.

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.

Nasdaq down nearly 10% from peak amid oil prices, Iran tensions, and Fed inflation concerns. Historical data shows corrections often create buying opportunities.

Toast stock plunged 43% despite record $608M free cash flow, as AI competition threatens software industry pricing power and switching costs.

Law firm investigates Zynex securities fraud claims; investors face April 2026 deadline for federal class action lawsuit over alleged revenue inflation and Tricare payment fraud.

INB.bio launches 2026 expansion strategy targeting Tanzania and 3-5 new countries across Africa and Southeast Asia, leveraging projected $9.8 trillion global wellness market.

Nvidia trades at 21x forward earnings—below growth stock averages—despite $215B revenue, 70%+ margins, and $1T GPU order guidance through 2027.

Three high-yield dividend stocks offer reliable long-term income: Realty Income (5.1% yield, 30+ years increases), Enterprise Products Partners (5.8% yield, 27 years increases), and Verizon (5.7% yield, 19 years increases).

TruBridge disclosed material accounting errors in 2023-2025 financials, triggering a 10.5% stock decline and spurring shareholder litigation.

HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.

Boston Scientific faces class action over false electrophysiology segment statements. Investors from July 2025–February 2026 may recover damages; lead plaintiff deadline May 4, 2026.

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.

$EOSE faces class action lawsuit over alleged false production capacity and performance claims. Lead plaintiff deadline: May 5, 2026.

S&P 500 down 4.95%, Nasdaq down 6.86% year-to-date through March 2026. Historically, bull markets outlast bear markets; S&P 500 returned 343% since 2000 despite multiple crises.

Rising oil prices from Middle East tensions ripple beyond energy sector, pressuring travel, logistics, and consumer goods companies to raise prices.

Bitcoin declined to $68,951 amid geopolitical tensions, while Pepeto raised $8.28M and approaches Binance listing. Institutional accumulation continues.

Nissay Asset Management adopts Virtu Financial's Triton trading platform after launching domestic operations in September, with international expansion planned for 2026.